Zack’s Investment Research Initiates Coverage of VeriTeQ Corporation
with an Outperform Rating

February 12, 2014 11:33 AM Eastern Standard Time

DELRAY BEACH, Fla.--(BUSINESS WIRE)--VeriTeQ Corporation (“VeriTeQ” or “Company”) (OTC Markets:VTEQ), a
provider of implantable medical device identification and radiation dose
measurement technologies, announced today that Zacks Investment Research
(“Zacks”) has initiated coverage of the Company with an outperform
rating.

Any opinions, judgments, estimates, or forecasts regarding the Company's
historical or predicted performance or operations made by Zacks are its
alone and do not represent opinions, judgments, estimates, or forecasts
of the Company or its management. The Company does not by its reference
to the research prepared by Zacks imply its endorsement or adoption of
or concurrence with such information, conclusions, or recommendations.

About VeriTeQ

VeriTeQ is focused on the unique device identification (“UDI”) of
implantable and reusable medical devices through its Q Inside Safety
Technology, and radiation dose measurement during radiation therapy.
VeriTeQ’s FDA cleared Q Inside Safety Technology acts as an electronic
serial number in breast implants and other implantable and reusable
medical devices that gives physicians and patients access to secure
online databases to retrieve device-specific data such as serial number,
manufacturer name, date of manufacture, lot number, volume, size, and
other data from the medical device manufacturer. Q Inside Safety
Technology also provides an extra level of protection to the patient in
the event of a recall or other safety event.

VeriTeQ’s radiation dosimeter, or biodosimetry, technologies include the
DVS SmartMarker® and OneDose®. DVS SmartMarker is the world’s first FDA
cleared, implantable, wireless radiation sensor, and is used to measure
the radiation dose delivered to a patient directly from the site of the
tumor during cancer treatment. DVS SmartMarker is cleared for use in
breast and prostate cancer patients. Its OneDose® adhesive technology is
FDA cleared for use in cancer patients being treated with external beam
radiation to measure radiation dose levels at the skin surface.

VeriTeQ’s intellectual property portfolio includes more than 100 patents
issued, patents pending, and patent licenses. VeriTeQ also has data
analytics capabilities related to information gathered by its
technologies.

Statements in this press release about our future constitute
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act of
1934, and as that term is defined in the Private Litigation Reform Act
of 1995. Such forward-looking statements involve risks and uncertainties
and are subject to change at any time, and our actual results could
differ materially from expected results. These risks and uncertainties
include, without limitation, VeriTeQ’s ability to commercially launch
its Q Inside Safety Technology; the Company’s ability to target the UDI
sector and medical device manufacturers; the Company’s ability to
commercialize its radiation dosimetry technologies; VeriTeQ’s ability to
raise capital; as well as other risks. Additional information about
these and other factors may be described in VeriTeQ’s Forms 10-Q, filed
on August 9, 2013 and November 14, 2013, and future filings with the
Securities and Exchange Commission The Company undertakes no obligation
to update or release any revisions to these forward-looking statements
to reflect events or circumstances after the date of this statement or
to reflect the occurrence of unanticipated events, except as required by
law.